Long Passeo-18 Lux drug-coated balloon for blocked leg arteries
Tests a long drug-coated balloon in peripheral arterial disease.
Key facts
- Who runs it
- KANDO Research
- Where
- Belgium4 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Single Arm Trial to Evaluate the Safety and Efficacy of the Long (> 150mm) PasseoTM-18 LuxTM Drug-coated Balloon in the Treatment of Subjects With Infrainguinal Stenotic, Restenotic or Occlusive Lesions
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 1 Jul 2026
- Expected to end
- Jan 2032
- Type of study
- Interventional
- Treatments tested
- Percutaneous Transluminal Angioplasty with the use of Passeo-18 Lux DCB
- Record updated
- 10 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with narrowed or blocked leg arteries (peripheral arterial disease). They will be treated with the Passeo-18 Lux drug-coated balloon.
- Age
- 18 to 99 years
- Sex
- All sexes
- Disease stage
- New narrowing, narrowing that came back after plain balloon treatment, or a full blockage in the leg arteries above or below the knee. The narrowing must be at least 70%, at least 3cm (1.2 in) long, in a vessel 2-7mm wide. Rutherford Class 2-5.
- Earlier treatment
- People who had bypass surgery on the target vessel cannot join.
- Biomarker or test result
- Imaging of the artery (angiography) must show ≥70% narrowing. After first widening with a balloon, less than 50% narrowing may remain.
Main reasons for not taking part
- Expected to live 1 year or less
- Pregnant, planning pregnancy, or planning to father a child during the study
- Planned major amputation of the treated leg
- Blood clot in the treated vessel
- One lesion reaching both above and below the knee
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Study participant is ≥ 18 years and ≤ 99 years old
- Lesion(s) in the infrainguinal arteries:; Lesion above the knee (ATK): Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau); Lesion below the knee (BTK): Target lesions involve arteries below the tibial plateau
- RVD 2-7mm
- De novo stenotic, restenotic post POBA, or occlusive lesion(s)
- Target lesion must have angiographic evidence of ≥70% stenosis
- Lesion length ≥ 3cm
- Successful crossing of the target lesion with the guide wire
- Successful predilatation, defined as residual stenosis <50% Rutherford Class 2-5
- Study participant is able to provide consent and has signed and dated the informed consent form
Who cannot take part
- Study participant is currently participating in another investigational drug or device study that has not reached its primary endpoint yet
- Prior bypass surgery of target vessel
- Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion)
- Known allergy to contrast media that cannot be adequately controlled with premedication
- Life expectancy ≤ 1 year
- Study participant is pregnant, planning to become pregnant, or father children during the course of the study
- Planned major amputation of the target limb
- Thrombus in the target vessel
- Study participant has a single target lesion that involves both ATK and BTK segments
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial will evaluate the study device, Passeo®-18 Lux® paclitaxel-releasing percutaneous transluminal angioplasty (PTA) balloon catheter for the treatment of new or recurring cholesterol-related blockages in the arteries of the lower leg.
Read full original descriptionShow less
The device that is used in this trial has been assessed in several previous studies for safety and effectiveness. The device is already approved for use in Europe. It has a "CE mark," which means it meets the European Union's safety, health and performance standards.
This trial is being done to gather additional information on how well the device works and how safe it is when used in everyday medical care with specific attention to the longer lengths of the balloon, as it comes in different sizes.
The group in the trial
- Passeo-18 Lux ArmTreatment being tested
All trial participants will be treated with the same Passeo-18 Lux drug coated balloon (which comes in different sizes).
Treatment: Percutaneous Transluminal Angioplasty with the use of Passeo-18 Lux DCB
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Single Arm Trial to Evaluate the Safety and Efficacy of the Long (> 150mm) PasseoTM-18 LuxTM Drug-coated Balloon in the Treatment of Subjects With Infrainguinal Stenotic, Restenotic or Occlusive Lesions
- Plain-language title
- Long Passeo-18 Lux drug-coated balloon for blocked leg arteriesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07385573, who can take part
- Record updated
- 10 September 2026